3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Sarcoma
1
Lymphoid
1
Gastrointestinal
1
CNS
1
Conditions
Sarcoma
2
Gliosarcoma
2
Glioblastoma
2
Stomach Neoplasms
1
Neuroblastoma
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Neoplasm Metastasis
1
Hematologic Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Brain Neoplasms
1
Interventions
repotrectinib
1
pembrolizumab
1
pamiparib
1
interferon gamma-1b
1
capmatinib
1
Trabectedin
1
Temozolomide
1
Radiation
1
Oncolytic Virotherapy
1
Irinotecan
1
Interferon-gamma
1
Immunotherapy
1
FANG vaccine
1
Doxorubicin
1
Dexamethasone
1
Cyclophosphamide
1
ARQ531
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
capmatinib
×
Sarcoma
×
Clear all
NCT06988475
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled